Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
0.8440
-0.0181 (-2.10%)
At close: Jul 20, 2026, 4:00 PM EDT
0.8790
+0.0350 (4.15%)
Pre-market: Jul 21, 2026, 4:31 AM EDT
Rein Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Rein Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 610.90% higher than the current stock price, while the lowest is $4.00 (+373.93%) and the highest is $8.00 (+847.87%).
Price Target: $6.00 (+610.90%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rein Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Initiates $4 | Buy | Initiates | $4 | +373.93% | Jul 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 → $8 | Buy | Reiterates | $10 → $8 | +847.87% | Jun 1, 2026 |
| Brookline Capital Markets | Brookline Capital Markets | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jan 21, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.54
EPS Next Year
-0.54
from -0.54
EPS and Forward PE are based on non-GAAP adjusted numbers.